| For: | Wang Z, Zhang RY, Xu YF, Yue BT, Zhang JY, Wang F. Unmasking immune checkpoint resistance in esophageal squamous cell carcinoma: Insights into the tumor microenvironment and biomarker landscape. World J Gastrointest Oncol 2025; 17(8): 109489 [PMID: 40837744 DOI: 10.4251/wjgo.v17.i8.109489] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v17/i8/109489.htm |
| Number | Citing Articles |
| 1 |
Haoyue Lai, Lu Qi, Zhixuan Lin, Zhongwen Li. The multidimensional regulatory network of the PD‑1/PD‑L1 axis in the esophageal squamous cell carcinoma microenvironment: Implications for novel combination therapies and precision immunotherapy (Review). Oncology Reports 2025; 55(1) doi: 10.3892/or.2025.9021
|
| 2 |
Zhifeng Qu, Xuewei Zheng, Anshun Zhao, Pei Wang, Shegan Gao, Qinan Yin. Mast cell driven immunometabolism as a therapeutic entry point in ESCC. Frontiers in Cell and Developmental Biology 2026; 14 doi: 10.3389/fcell.2026.1830394
|
| 3 |
Xuejun Guo, Shuhan Ma, Jingwen Wang, Yilin Fu, Wenxue Ma. Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology. Frontiers in Immunology 2026; 16 doi: 10.3389/fimmu.2025.1709852
|
| 4 |
Yi Xu, Xianhao Wang, Yujiao Sun, Xinyi Ye, Yingyin Gao, Luxi Li, Yue Wu, Keyi Zhou, Yunzhi Pan, Sai Ma. Establishment and multi-omics characterization of a PD-1-resistant murine esophageal squamous cell carcinoma cell line. Biochemical and Biophysical Research Communications 2026; 828 doi: 10.1016/j.bbrc.2026.154109
|